Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T22:01:13.492Z.
Calculation as of: 2026-10-06T22:01:13.492Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c02d81e284155bdcda1783dec911e9c0a395e203238f61c1cccf60d236910ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$8.93B
Price/FCF Ratio
95.08
TTM Avg
1012.95
3Y Avg
992.25
5Y Avg
992.25
Market Cap
$8.92B
Price/FCF Ratio
68.30
TTM Avg
96.70
3Y Avg
52.90
5Y Avg
52.90
Market Cap
$9.21B
Price/FCF Ratio
98.08
TTM Avg
132.35
3Y Avg
74.15
5Y Avg
69.02
Market Cap
$8.72B
Price/FCF Ratio
N/A
TTM Avg
34.88
3Y Avg
34.77
5Y Avg
34.77
Market Cap
$8.67B
Price/FCF Ratio
N/A
TTM Avg
106.69
3Y Avg
106.69
5Y Avg
68.15
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $8.97B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $8.93B | 95.08 | 1012.95 | 992.25 | 992.25 |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 68.30 | 96.70 | 52.90 | 52.90 |
| Bruker Corporation (BRKR)vs › | $9.21B | 98.08 | 132.35 | 74.15 | 69.02 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | N/A | 34.88 | 34.77 | 34.77 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | N/A | 106.69 | 106.69 | 68.15 |
| Insulet Corp. (PODD)vs › | $9.33B | 31.28 | 39.52 | 71.17 | 71.17 |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 1.93 | 3.94 | 6.21 | 7.86 |
| Vaxcyte, Inc. (PCVX)vs › | $9.63B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 37.37 | 41.45 | 45.70 | 45.70 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute